Beyond Ro5 Free Ligand Conformational and Dynamical Determinants of Passive Permeability: Computational and Experimental Synergies 
Amber Y.S. Balazs, Director, US Analytical, Structural, and Chromatography (ASC) Team, Early Oncology Chemistry NMR Specialist, AstraZeneca
Presentation Title to Be Announced
James Dowling, Senior Director, Medicinal Chemistry, Morphic Therapeutic
Modeling Ternary Complexes with Molecular Glues: Making Sense of a Sticky Situation 
Michael Drummond, Scientific Applications Manager, Chemical Computing Group
Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9/cyclin T1 for MYC-dependent Cancers 
Dave Freeman, Director, Hit Discovery Chemistry, Kronos Bio
Selective Small Molecule Activation of PKG1α: Structure and Function 
Essam Metwally, Principal Scientist, Merck Research Labs
Discovery of Selective and Highly Potent RIPK1 Type III Inhibitors for the Treatment of Neurodegenerative Diseases 
Lorena Rico, Senior Scientist, Discovery Chemistry, Merck

April 25 - Workshops
Morning Sessions
08:15-09:00
Morning Coffee
Registration (check-in/badge pick-up)
09:00-10:00
Small Molecule Docking 
Protein-Ligand Interaction Analysis / Protein-Ligand Docking / Pharmacophore Modeling / High-throughput Docking / Template-Based Docking
10:00-10:30
Morning Break
10:30-12:00
Fragment-based Design: Scaffold Hopping, Fragment Growing and Bioisosteric Replacements 
Scaffold Replacement / Ligand Growing / Bioisosteric Transformations / Pharmacophore Modeling
12:00-13:00
Workshop Lunch
April 25 - Scientific Presentations
Afternoon Sessions
12:30-13:30
Registration (check-in/badge pick-up)
13:30-13:35
Opening Remarks
13:35-15:35
Scientific Presentations | Session 1
15:35-16:05
Afternoon Break
16:05-18:05
Scientific Presentations | Session 2
18:05-18:10
Closing Remarks
18:10-19:15
Social Reception